Arthur G. Lipman, Pharm.D. - International Association for Hospice ...
Arthur G. Lipman, Pharm.D. - International Association for Hospice ...
Arthur G. Lipman, Pharm.D. - International Association for Hospice ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Arthur</strong> G. <strong>Lipman</strong><br />
Page 15<br />
Editorials (continued)<br />
<strong>Lipman</strong> AG. J Pain Palliat Care <strong>Pharm</strong>acother. 2007:21<br />
172. Addressing the growing discordance between clinicians and regulators (1):3-4<br />
173. The Declarations of Venice of 1983 and 2006: Two ef<strong>for</strong>ts to improve palliative care. (1):4-6<br />
174. Addressing the need <strong>for</strong> knowledge about pharmacotherapy in palliative care (2):3-4<br />
175. Advocate <strong>for</strong> improving pain control (3):3-4<br />
176. The emotional dimensions of pain. (4): 3-4.<br />
<strong>Lipman</strong> AG. J Pain Palliat Care <strong>Pharm</strong>acother. 2008:22<br />
177. The indexed pain literature (1): 3-4.<br />
178. Has the multiple prescription debacle truly been resolved (2):3-4.<br />
179. Why we must listen to our patients. (3):198-9.<br />
180. Pain management and palliative care as a basic human right. (4):268.<br />
181. Educate and advocate. (4):268-9.<br />
<strong>Lipman</strong> AG. J Pain Palliat Care <strong>Pharm</strong>acother. 2009:23<br />
182. Drug policy, politics and the law. (1): 2-3<br />
183. Welcome to In<strong>for</strong>maworld (1): 3.<br />
184. It is time to remove propoxyphene from clinical practice. (2):104-5.<br />
185 The pain drug fraud scandal: implications <strong>for</strong> clinicians, investigators and journals (3): 216-18.<br />
186. The Food and Drug Administration opioid risk evaluation and mitigation strategy. (3): 219-21.<br />
187. Broadening the journal’s perspective. (3):222.<br />
188. Political activism to improve pain care. (4): 334-5.<br />
189. It is time to discourage dietary supplements and homeopathic remedies in pain patients. (4): 335.<br />
<strong>Lipman</strong> AG. J Pain Palliat Care <strong>Pharm</strong>acother. 2010:24<br />
190. Access to unapproved drugs. (1):2<br />
191. Psychopathology and pain. (1):3<br />
192. The FDA and Congress: differing Agendas (2):116-17<br />
193. Our Dynamic Editorial Board (2):118.<br />
194. Risks and Benefits of Opioid Availability (3)198-9.<br />
195. Narratives on Pain, Suffering and Relief. (4)328-29.<br />
196. Dietary Supplements: Call to Action. (4)330-32.<br />
<strong>Lipman</strong> AG. J Pain Palliat Care <strong>Pharm</strong>acother. 2011:25<br />
197. The Role <strong>for</strong> Narrative in the Era of Evidence-Based Care. (1):2-3.<br />
198. Urine Drug Screens: A Double-Edged Sword. (2):112.
Change language